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Introduction: Epigenetic inactivation of tumor suppressor genes 
is involved in the development of malignant pleural mesothelioma 
(MPM). ZIC1, a potential tumor suppressor gene involved in regulat-
ing cell growth and apoptosis, was investigated in MPM cell lines 
and tumors.
Methods: ZIC1 expression and promoter methylation were evaluated 
in MPM cell lines and tumor samples by quantitative polymerase 
chain reaction (PCR), Combined Bisulfite Restriction Analysis, and 
methylation-specific PCR. ZIC1 was reexpressed in cell lines and 
functional effects were assessed. miRNA expression was quanti-
fied by microarray and reverse transcription quantitative PCR. ZIC1 
knockdown and miRNA inhibitors were used to study the relation-
ship between ZIC1 and miRNA expression and confirmed by chro-
matin immunoprecipitation PCR.
Results: ZIC1 expression was low in MPM cells, and was correlated 
with ZIC1 promoter methylation and reversed upon decitabine treat-
ment. ZIC1 reexpression inhibited proliferation and invasion in MPM 
cells whereas knockdown enhanced the growth of MeT-5A. In MPM 
tumor samples ZIC1 expression was either low or undetectable, with 
promoter methylation observed in 16 of 24 cases. The overexpression of 
miR-23a and miR-27a was reduced by ZIC1 reexpression, with inhibi-
tors of miR-23a or miR-27a reducing colony formation. miR-23a over-
expression was also associated with shorter survival of MPM patients.
Conclusion: ZIC1 is down-regulated in MPM through promoter 
methylation and acts as a tumor suppressor through down-regulation 
of its direct targets miR-23a and miR-27a.
Key Words: Epigenetic gene silencing, Malignant mesothelioma, 
ZIC1, Methylation, miRNA.
(J Thorac Oncol. 2013;8: 1317-1328)
Asbestos-induced carcinogenesis is initiated by the depo-sition of asbestos fibers and the consequent release of 
proinflammatory molecules such as tumor necrosis factor-α 
by macrophages1 and high-mobility group box 1 protein 
(HMGB-1) from mesothelial cells.2 The importance of 
chronic inflammation is underlined by the increase inci-
dence of malignant peritoneal mesothelioma in patients with 
familial Mediterranean fever.3,4 Inflammation is also related 
to tumor suppressor gene (TSG) silencing.5 Cumulative 
studies of aberrant DNA methylation in human cancers 
revealed high rates of aberrant promoter methylation in a 
subset of cancers,6 which may also play a role in asbestos 
carcinogenesis.7,8
Malignant mesothelioma is resistant to most antican-
cer agents, and it has been suggested that this resistance is 
associated with alterations in genes involved in the apoptotic 
response.9 The molecular basis of these changes is not well 
understood. In an effort to better understand drug resistance 
and apoptotic response, we investigated the role of ZIC1, a 
gene involved in apoptosis.10,11 ZIC genes encode a conserved 
family of zinc-finger transcription factor proteins,12 which 
play a critical role in the development of the neural tube, left–
right symmetry, and muscular and skeletal development.13,14 
Apart from the regulation of cell proliferation and differentia-
tion of the dorsal neural tube,15 ZIC1 has been shown to inhibit 
the PI3K/Akt pathway and to be able to induce apoptosis in 
colorectal cancer.10
In this study, with the use of malignant pleural meso-
thelioma (MPM) cell cultures and MPM tumor samples, 
we demonstrate that silencing of ZIC1 via DNA hyper-
methylation is a frequent event and that ZIC1 silencing is 
correlated with the increased expression of a number of 
miRNAs. Reexpression of ZIC1 led to the inhibition of 
colony formation and migration of MPM cells in vitro, 
as well as down-regulation of apoptosis-related miR-23a, 
providing an epigenetic link between ZIC1 expression and 
apoptosis.
MATERIALS AND METHODS
Cell Lines and Cell Culture
Five MPM cell lines (H2052, H2452, H28, H226, and 
MSTO) and the immortalized mesothelial cell line MeT-5A 
were obtained from American Type Culture Collection (ATCC, 
Copyright © 2013 by the International Association for the Study of Lung 
Cancer
ISSN: 1556-0864/13/0810-1317
ZIC1 Is Silenced and Has Tumor Suppressor Function  
in Malignant Pleural Mesothelioma
Yuen Yee Cheng, PhD,* Michaela B. Kirschner, PhD,* Ngan Ching Cheng, PhD,* Sumedha Gattani, MSc,* 
Sonja Klebe, FRACS,† J. James B. Edelman, PhD,‡ Michael P. Vallely, FRACS,‡  
Brian C. McCaughan, FRACS,‡ Hong Chuan Jin, PhD,§ Nico van Zandwijk,  PhD,* and Glen Reid,  PhD*
*Asbestos Diseases Research Institute, University of Sydney, Sydney, 
Australia; †Department of Anatomical Pathology, Flinders Medical 
Centre, Adelaide, Australia; ‡Cardiothoracic Surgical Unit, Royal Prince 
Alfred Hospital; The Baird Institute, Sydney Medical School, University 
of Sydney, Sydney, Australia; and §Biomedical Research Center, Sir 
Runrun Shaw Hospital, Zhejiang University, Hangzhou, China.
Disclosure: This work was supported by a generous donation from the 
Asbestos Disease Foundation of Australia (to Y.Y.C.) and a grant from the 
Dust Diseases Board of New South Wales (to G.R.). The authors declare 
no other conflict of interest.
Address for correspondence: Yuen Yee Cheng, Asbestos Diseases Research 
Institute, University of Sydney, PO Box 3628, Rhodes, NSW 2139, 
Australia. E-mail: yycheng@sydney.edu.au
ORIGINAL ARTICLE
1318 Copyright © 2013 by the International Association for the Study of Lung Cancer
Cheng et al. Journal of Thoracic Oncology  •  Volume 8, Number 10, October 2013
Manassas, VA). The primary mesothelioma cell line MM0516 
was generated at the University of Queensland Thoracic 
Research Centre (The Prince Charles Hospital, Brisbane, 
Australia), and Ren cells17 were provided by Laura Moro of the 
University of Piemonte Orientale A. Avogadro, Novara, Italy. 
Normal human mesothelial cells (HMCs) were isolated from 
pericardial fluid collected during cardiac surgery. Cells were 
cultured at 5% CO
2
, 37°C, and 95% humidity in RPMI 1640 
(MPM cells), DMEM (MeT-5A) or Ham’s F12 (Ren) with 
10% fetal bovine serum (FBS), HMCs were cultured in RPMI 
supplemented with 15% FBS, 0.4 µg/ml hydrocortisone, 1% 
penicillin/streptomycin, and 0.25 µg/ml Fungizone. All media 
and FBS were from Life Technologies (Carlsbad, CA).
Tumor Samples
The tumor samples used in this study are part of a 
previously reported series on MPM patients who underwent 
extrapleural pneumonectomy at Royal Prince Alfred Hospital 
or Strathfield Private Hospital, Sydney, Australia, between 
1994 and 2009.18 All specimens were formalin-fixed, paraffin-
embedded (FFPE) tumor blocks (Table 1). The tumor content 
was marked on whole sections to guide subsequent laser-cap-
ture microdissection. This work was conducted as part of a 
larger study aimed at identifying prognostic factors in MPM 
and was approved by the Human Research Ethics Committee 
at Concord Repatriation General Hospital, Sydney. Written 
informed consent from all participants was obtained.
Decitabine Treatment and 
Western Blot Analysis
MPM cells were seeded at 5 × 105 cells in a 10 cm2 
dish and 24 hours later treated with the demethylating agent 
5-aza-2′deoxycytidine (decitabine; 2 µM) for 5 days with drug 
refreshed every 24 hours. Cells were then harvested for DNA, 
RNA (detailed below), and protein isolation. For Western blot 
analysis, cell lysates were prepared with RIPA buffer (Pierce, 
Rockford, IL) plus Complete Protease Inhibitors (Roche 
Diagnostics, Mannheim, Germany) according to the manu-
facturers’ instructions. Protein concentration was determined 
by BCA assay (Pierce), and cell lysates (40 μg per lane) were 
separated on sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis under reducing conditions before transfer to 
nitrocellulose, using the Trans-Blot Turbo Transfer System 
(Bio-Rad, Hercules, CA), and immunoblotted using a mouse 
monoclonal antibody against ZIC1 (Sigma-Aldrich, St. Louis, 
MO) at a dilution of 1:100. Immunoreactive proteins were 
detected using antimouse horseradish peroxidase–conjugated 
secondary antibody and SuperSignal West Femto (Pierce). The 
membranes were stripped with Restore Western Blot Stripping 
Buffer (Pierce) and immunoblotted using a 1:1000 dilution of a 
mouse monoclonal antibody against β-actin (Sigma-Aldrich). 
Imaging was carried out using a Gel Logic 2200 Imaging 
System (Kodak) under nonsaturating conditions.
Analysis of DNA Methylation
Genomic DNA was extracted from MPM cell lines using 
the DNA mini kit (Qiagen, Valencia, CA) and from MPM FFPE 
samples using the FFPE DNA minikit (Qiagen). The methylation 
status of the ZIC1 promoter in MPM cell lines was determined 
by methylation-specific PCR (MSP) and Combined Bisulfite 
Restriction Analysis (COBRA). Briefly, 2 µg of genomic DNA 
was bisulfite treated with the Zymo DNA Modification Kit 
(Zymo Research, Orange, CA) and resuspended in 50 µl H
2
O 
(~40 ng/µl). Bisulfite-treated DNA was used as a template for 
MSP and COBRA analysis. Two microliters of bisulfite-treated 
DNA was amplified in a reaction mixture containing ×1 poly-
merase chain reaction (PCR) buffer, 1.25 mM each deoxynucle-
otide triphosphate mixture, 0.5 µ M forward and reverse primer, 
and 1 unit of AmpliTaqGold polymerase (Life Technologies). 
PCR was carried out on a MultiGene Gradient thermal cycler 
(Labnet International Inc, Woodbridge, NJ). PCR products 
from MSP analysis were then separated in nondenaturing poly-
acrylaminde gels and photographed after staining with ethid-
ium bromide. OLIGO 6 software (Molecular Biology Insights, 
Cascade, CO) was used for designing primers specific for meth-
ylated and unmethylated alleles in MSP (Table 2). CpGenome 
universal methylated DNA (Millipore, Billerica, MA) was used 
as positive control for methylation, and normal buffy coat (from 
a healthy donor) was used as a control for the unmethylated 
locus in each amplification. For COBRA, PCR amplification 
of 2 µl of bisulfite-treated DNA using AmpliTaqGold produced 
an amplicon of 455 base pair, encompassing the ZIC1 promoter 
region from +945 to +1399 base pair relative to the transcription 
start site (within a longer CpG-containing region from +187 to 
+1716). This region contained 53 CpG dinucleotides and seven 
BstUI restriction sites. The PCR products were digested with 
BstUI (New England Biolabs, Ipswich, MA) for 2 hours at 
60°C and analyzed by nondenaturing polyacrylamide gel elec-
trophoresis and visualized after ethidium bromide staining.
Reverse Transcription and 
Quantitative Real-Time PCR
Total RNA was extracted from cell lines using Trizol 
reagent (Life Technologies) and FFPE samples using Qiagen 
FFPE RNeasy kit according to the manufacturers’ instruc-
tions. Reverse transcription (RT) reactions were performed 
using 200 ng of total RNA with MMLV first strand cDNA 
kit (Promega, Madison, WI) following the manufacturer’s 
protocol. The expression of ZIC1 mRNA was determined 
by quantitative real-time PCR using the Brilliant II SYBR 
Green QPCR Master Mix (Stratagene/Agilent Technologies, 
Santa Clara, CA) and the Mx3000P QPCR System (Agilent 
Technologies). Probe Design software (Roche Diagnostic) 
was used for designing PCR primers (Table 2). The reference 
gene used was 18S. ZIC1 mRNA expression levels were deter-
mined using the 2−∆∆Cq method19 with normalization to 18S.
Analysis of miRNA Expression by 
NCode miRNA Microarray
miRNA expression profiling in MeT-5A, H28, MSTO, 
and MM05 cells was performed using the NCode Human 
miRNA Microarray V3 system (Life Technologies) follow-
ing the manufacturer’s instructions. Briefly, 1 µg of total RNA 
from each sample was labeled with Alexa Fluor 5 dye using 
the NCode Rapid miRNA Labeling System, then hybridized 
to NCode Array slides overnight. Slides were scanned using an 
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Axon GenePix 4000B Microarray Scanner (Molecular Devices, 
Sunnyvale, CA). Background-corrected fluorescence signals 
were used for analysis of differential miRNA expression using 
the GeneSpringGX 11.0 software (Agilent Technologies). Data 
were processed applying thresholding of the signal values to 1, 
followed by normalization to the 75th percentile with baseline 
transformation to the control sample (MeT-5A).
RT-qPCR for miRNA Expression Analysis
Levels of miRNAs were determined using miRNA-spe-
cific TaqMan assays (Life Technologies). The RT step contained 
equimolar amounts of primers specific for candidate miRNAs 
and controls, and was carried out using the TaqMan miRNA 
Reverse Transcription Kit (Life Technologies) with the follow-
ing reaction conditions: 30 minutes at 16°C, followed by 30 
minutes at 42°C and 5 minutes at 85°C. The quantitative PCR 
was carried out in triplicate with no RT and no template con-
trols. Reactions were set up manually and run on a Stratagene 
Mx3000P instrument. Cq (quantification cycle) values were 
determined using adaptive-baseline and background-based 
threshold (cycle range, 5–8) using the MxPro Mx3000P v4.10 
software (Agilent Technologies). Levels of candidate miRNAs 
are expressed relative to MeT-5A calculated using the 2−∆Cq 
method.19 In case of FFPE samples relative miRNA expressions 
were calculated using the 2−∆∆Cq method19 with normalization to 
RNU6B as reference gene and calculation of relative expres-
sion as compared with the average ∆Cq of all tumor samples.
Expression Plasmids, siRNAs, miRNA 
Inhibitors and Transfection
The pcDNA3.1(+)ZIC1 expression construct was gen-
erated by PCR cloning, sequence verified and subcloned into 
pcDNA3.1-TOPO expression vector (Life Technologies) as 
described.20 Plasmids were introduced into cells by transfec-
tion with Lipofectamine LTX (Life Technologies) as per the 
manufacturer’s instructions. For ZIC1 knockdown experiments, 
siRNAs (Integrated DNA Technologies Inc, Coralville, IA; 
Table 2) were reverse transfected into cells using Lipofectamine 
TABLE 1.  Patient Demographics
Sample ID Sex Age Histotype Survival (mo) Analysis
EPP2 M 59 Epithelioid 53.68 mRNA, methylation, miRNA
EPP7 M 44 Epithelioid 49.81 Methylation, miRNA
EPP14 F 38 Epithelioid 33.61 mRNA, methylation
EPP17 M 50 Epithelioid 37.65 mRNA, methylation
EPP19 F 60 Epithelioid 6.37 Methylation, miRNA
EPP24 M 53 Epithelioid 9.56 mRNA, methylation
EPP28 F 32 Epithelioid 63.93 mRNA, methylation, miRNA
EPP31 M 60 Biphasic 5.42 mRNA
EPP32 M 58 Epithelioid 41.4 mRNA
EPP34 M 66 Epithelioid 6.44 mRNA, methylation, miRNA
EPP35 F 48 Epithelioid 70.74 Methylation, miRNA
EPP36 M 70 Epithelioid 6.93 mRNA, miRNA
EPP38 M 61 Epithelioid 23.16 Methylation
EPP39 M 64 Epithelioid 45.83 mRNA, methylation
EPP45 M 64 Epithelioid 60.71 mRNA, methylation, miRNA
EPP46 M 54 Epithelioid 6.9 mRNA, miRNA
EPP48 F 48 Epithelioid 44.16 mRNA
EPP50 M 54 Epithelioid 72.9 mRNA, methylation, miRNA
EPP51 M 51 Biphasic 3.42 mRNA, methylation
EPP52 M 61 Epithelioid 8.28 mRNA, methylation, miRNA
EPP54 F 63 Epithelioid 2.07 mRNA, methylation, miRNA
EPP59 M 52 Biphasic 13.73 mRNA, methylation
EPP62 M 67 Epithelioid 9.36 Methylation
EPP65 M 64 Epithelioid 6.93 mRNA, miRNA
EPP69 F 49 Epithelioid 90.48 mRNA, methylation, miRNA
EPP72 M 47 Epithelioid 1.94 mRNA, methylation, miRNA
EPP74 M 57 Epithelioid 8.34 mRNA, methylation
EPP75 M 37 Epithelioid 48.66 mRNA, methylation, miRNA
EPP77 M 56 Biphasic 2.56 mRNA, methylation
EPP78 F 59 Epitheliod 14.52 mRNA, methylation
EPP79 M 56 Epithelioid 10.32 mRNA
EPP, extrapleural pneumonectomy.
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RNAiMAX (Life Technologies) at a final concentration of 
1 nM as previously described.21 The miRNA inhibitors (Exiqon, 
Vedbaek, Denmark) are listed in Table 2; they were used at con-
centrations indicated and transfected as described for siRNAs.
Immunofluorescence of ZIC1 Expression
Cells transfected with a ZIC1 expression construct or 
empty vector transfected cells were fixed with 4% paraformal-
dehyde (Sigma, St. Louis, MO) in phosphate-buffered saline 
(PBS) for 15 minutes, washed three times with PBS and per-
meabilized with 0.2% Triton X-100 in PBS for 5 minutes. Fixed 
cells were blocked with PBS containing 0.1% Triton and 10% 
FBS for 1 hour at room temperature. For immunostaining, cells 
were incubated for 2 hour at room temperature with mouse 
anti-ZIC1 antibody at 2.5 µ g/ml (Sigma) in blocking solution. 
After three washes with PBS, cells were incubated for 1 hour 
at room temperature with an Alexa Fluor 488-labeled rabbit 
antimouse antibody (Life Technologies). Nuclear counterstain-
ing was performed with 0.5 µ g/ml DAPI. Immunostained cells 
were observed under a fluorescence microscope.
Chromatin Immunoprecipitation PCR
MPM cells were transfected with ZIC1 flag-tag expres-
sion vector or empty vector for 48 h, fixed with 4% formal-
dehyde, washed, lysed, and sonicated until chromatin was 
sheared to an average DNA fragment length of 0.2 to 1.0 kb. 
DNA samples were subjected to chromatin immunoprecipita-
tion (ChIP)-PCR using SimpleChIP Enzymatic Chromatin IP 
Kit (Cell Signalling, Danvers, MA) according to the manu-
facturer’s instructions. After immunoprecipitation with an 
anti-FLAG antibody at 20 ng/ml, PCR was performed with 
the primers specific for the miR-23a/27a promoter (Table 2). 
Briefly 2 µl of immunoprecipitated DNA was amplified in a 
reaction mixture containing ×1 PCR buffer, 1.25 mM of each 
deoxynucleotide triphosphate, 0.5 µ M forward and reverse 
primer, and 1 unit of AmpliTaqGold DNA polymerase (Life 
Technologies). PCR was carried out on a MultiGene Gradient 
thermal cycler (Labnet International Inc). PCR products were 
then separated in nondenaturing polyacrylaminde gels and 
photographed after staining with ethidium bromide.
Proliferation Assay
The rate of in vitro cell proliferation was assessed by 
quantifying increases in DNA measured by an SYBR-green–
based assay. MPM cells were transfected with a ZIC1 expres-
sion construct or vector control in 96-well plates, and medium 
was changed 24 hours posttransfection. After 48 hours post-
transfection, medium was removed and the plate was frozen. 
Relative cell numbers were determined by staining with 200 
µl per well of SYBR Green I (Life Technologies) 1:4000 
in a hypotonic lysis buffer (10 mM Tris HCl [pH 8], 5 mM 
ethylenediaminetetraacetic acid, 0.1% Triton X-100) over-
night in the dark at 4°C and then quantified by fluorimetry at 
535 nm with 485 nm excitation, measured using a FLUOstar 
Optima (BMG LabTech, Ortenberg, Germany). Fluorescence 
intensity in ZIC1-transfected cells was presented as a 
TABLE 2.  Primers, siRNAs, and miRNA Mimics/Inhibitors Used in This Study
qPCR Primers
Target Forward Reverse T
m
, Cycle
ZIC1 COBRA 5′-gttttgggttattattattatt-3′ 5′-gcaaataaactcttacttaataa-3′ 52°C, 40
ZIC1 MSP 5′-ggattttttgtttcgtaatc-3′ 5′-cccgttaaccacgttaaacg-3′ 60°C, 40
ZIC1 USP 5′-gggattttttgttttgtaatt-3′ 5′-cccattaaccacattaaaca-3′ 60°C, 40
ZIC1 mRNA 5′-aaactggttaaccacatccgc-3′ 5′-ctcaaactcgcacttgaagg-3′ 60°C, 40
18S 5′-gccgctagaggtgaaattcttg-3′ 5′-cattcttggcaaatgctttcg-3′ 60°C, 25
siRNAs
  ZIC1 Antisense 5′-UUCUGGAAACUAAAGUGUACAUACGAG-3′
Sense 5′-CGUAUGUACACUUUAGUUUCCAGAA-3′
  Control Antisense 5′-AAGCAACUUGGUAAGACUCGUGUGG-3′
Sense 5′-CCACACGAGUCUUACCAAGUUGCUU-3′
miRNA qPCR assays miRNA inhibitors
Target Assay ID Target Cat. No.
hsa-miR-23a 000399 hsa-miR-23a Ex-412527-00
hsa-miR-27a 000408 hsa-miR-27a Ex-410167-00
hsa-miR-30a 000417 hsa-miR-30a Ex-410187-00
hsa-miR-30b 000602 hsa-miR-30b Ex-410189-00
hsa-miR-16 000391 hsa-miR-16 Ex-410084-00
RNU6B 001093 Antisense control A Ex-199004-00
ChIP PCR
Target Forward Reverse Tm, Cycle
miR23a/27a Promoter5′-gatgggatttgcttcctgtca-3′ 5′-gagctcagggtcggttgga-3′ 59°C, 40
MSP, methylation-specific PCR; COBRA, Combined Bisulfite Restriction Analysis; ChIP-PCR, chromatin immunoprecipitation PCR; PCR, polymerase chain reaction; qPCR, 
quantitative PCR; USP, unmethylated specific PCR.
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percentage of intensity of control cells. Each experiment was 
performed in triplicate.
Agarose Spot Invasion Assay
Invasive ability of ZIC1-transfected and control MPM 
cells was measured using an agarose spot assay done according 
to the Wiggins22 protocol with modification. Briefly, 1% low-
melting agarose (PBS, 0.4% FBS) was melted at 50°C. A spot 
consisting of 7.5 µl agarose solution was added to each well of a 
24-well culture plate and allowed to cool for ~5 minutes at 4°C. 
Once set, 200 µl of 1% Geltrex (Life Technologies) was then 
added to each well and kept at 4°C overnight. Residual Geltrex 
was aspirated and 1.2 × 105 cells were seeded in each well. At 24 
hours, 10 µg/ml Mitomycin C (Sigma) was added to stop cell 
division. At 48 hours and 72 hours postseeding, microscopic 
imaging was performed with a 20× objective, and for each spot 
we recorded the field that contained the highest apparent num-
ber of motile cells penetrating most further underneath the aga-
rose spot. Each experiment was performed in triplicate.
Colony Formation and Growth in Soft Agar
Cells were plated in 96-well culture plates at 2500 cells 
per well and transferred to six-well plate 24 hours posttrans-
fection. After incubation for 10 to 14 days at 37°C, cells were 
fixed with 70% ethanol and stained with 0.1% Crystal violet. 
The plates were then photographed for colony counting. Each 
experiment was performed in triplicate. Growth in soft agar 
was initiated at the same time as previously described.47 Cells 
were reseeded in 2 ml 0.3% noble agar (Sigma) with RPMI 
and 20% FCS in a six-well plate over a 3-ml layer of solidi-
fied RPMI (or DMEM or F12)/10% FCS and 0.6% agarose. 
The cells were fed by adding 200 µl RPMI (or DMEM or 
F12)/10% FBS. After 4 weeks the colonies were stained with 
Crystal violet and photographed.
Annexin V and Propidium Iodide  
Apoptosis Assays
To assess apoptosis, cells transfected with a ZIC1 expres-
sion vector or empty vector were seeded on six-well plates at a 
density of 3 × 105 cells per well in RPMI 1640 containing 10% 
FCS. After incubation for 48 hours, cells were harvested and 
washed three times with PBS. Cells were stained with fluores-
cein isothiocyanate (FITC) Annexin V Apoptosis Detection Kit 
(BD Biosciences, Franklin Lakes, NJ) according to the manu-
facturer’s instructions. The cells were incubated for 15 minutes 
at room temperature in the dark. Labeled cells were counted 
by Accuri C6 flow cytometer (BD Biosciences) within 30 
minutes. Performance validation of the Accuri C6 flow cytom-
eter was done using 6 and 8 peak fluorescent bead mixtures 
provided by the manufacturer (Accuri, Ann Arbor, MI), and 
according to their instructions. Annexin-V-FITC labeling was 
measured at 533/30 nm on the FL-1 channel (FITC-detector) 
and PI staining at 585/40 nm on the FL-2-channel (phycoery-
thrin-detector). The flow cytometer was routinely operated at 
the Slow Flow Rate setting (14 μl sample per minute), and data 
acquisition for a single sample typically took 3 to 5 minutes. 
For each sample 10,000 events were counted and cell cycle was 
analyzed. Each experiment was performed in triplicate.
Statistical Analysis
Student’s t test was used to compare the difference in 
proliferation of ZIC1- and control transfected cells. Two-tailed 
independent samples t test was used to compare the differ-
ences in miRNA expression in long versus short survivors. 
Statistical calculations were done using SPSS version 18.0 for 
Windows (SPSS, Inc, Chicago, IL). A p value less than 0.05 
was taken as statistically significant.
RESULTS
ZIC1 is Expressed in Normal Mesothelial 
Cells but Silenced in MPM Cell Lines
The expression of ZIC1 protein in mesothelial and 
MPM cell lines was analyzed by Western blot (Fig. 1A). The 
mesothelial cell line MeT-5A showed high basal levels of 
ZIC1 protein. A low level of ZIC1 protein expression was also 
detectable in MSTO cells, and this increased after decitabine 
treatment. There was no detectable expression of ZIC1 in 
either H28 or H226, and this was not changed by decitabine 
treatment. The expression of ZIC1 mRNA was then analyzed 
by RT-qPCR (Fig. 1B). High levels of ZIC1 expression were 
found in the immortalized cell line MeT-5A. However, in 
three of five MPM lines from ATCC, ZIC1 expression was not 
detected and relatively low levels of expression were found in 
two primary MPM lines (MM05 and Ren; Fig. 1B). Expression 
was increased in all cell lines after treatment with the demeth-
ylating agent decitabine (Fig. 1C), suggesting a role for meth-
ylation in the reduced expression of ZIC1 in MPM cell lines.
ZIC1 Is Silenced through DNA 
Hypermethylation in MPM Cells
Analysis of the methylation status of ZIC1 in MPM cell 
lines was carried out by a combination of MSP and COBRA. 
MSP revealed promoter methylation in the six MPM cell lines 
with undetectable or low expression of ZIC1 mRNA, whereas 
partial methylation was seen in MSTO cells (Fig. 1D). 
COBRA analysis was used to further compare the methylation 
status of ZIC1 in HMCs and MPM cell lines. A representa-
tive COBRA analysis of the ZIC1 gene in MPM cell lines is 
shown in Figure 1B. No methylation of ZIC1 was detected in 
HMCs, whereas DNA hypermethylation was detected in all 
MPM lines (Fig. 1E).
After treatment with decitabine (2 µM, 5 days), ZIC1 
was reexpressed in six MPM lines in which basal levels 
of ZIC1 mRNA were undetectable or relatively low. In the 
MSTO cells, which showed partial demethylation, decitabine 
treatment also led to an up-regulation of ZIC1 (Fig. 1C). 
ZIC1 expression was not significantly affected by decitabine 
treatment in the MeT-5A line (Fig. 1A–C). Analysis of the 
effects of decitabine treatment by MSP and COBRA also 
resulted in a reduction in the intensity of methylated bands 
along with a strong increase in the unmethylated band in 
H2052, H2452, H28, H226, and MSTO cells. Together these 
data suggest that the lack of detectable ZIC1 expression in 
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untreated cells was a result of DNA hypermethylation of the 
ZIC1 promoter (Fig. 1D, E).
ZIC1 Is Hypermethylated in MPM Tumors
To determine the clinical significance of ZIC1, we ana-
lyzed the mRNA expression and the methylation status of the 
ZIC1 promoter in tumor blocks from 24 MPM patients. The 
result from RT-qPCR showed that ZIC1 mRNA expression 
was present at very low or undetectable levels in MPM tumor 
samples, and when present, levels were much lower than those 
observed in MeT-5A cells (Fig. 2A). MSP analysis revealed 
methylation of ZIC1 in 67% (16 of 24; Fig. 2B) of MPM sam-
ples. Both RT-qPCR and MSP analysis revealed ZIC1 mRNA 
silencing because of DNA methylation in FFPE samples.
ZIC1 Affects Cell Invasion and Colony 
Formation of MPM Cells
The high frequency of ZIC1 silencing by DNA methyla-
tion in MPM cell lines suggested a potential tumor suppres-
sor role for this gene. To test this, we overexpressed ZIC1 in 
MPM cells using a ZIC1 expression construct, which led to 
increased ZIC1 protein expression in MPM cells (Fig. 3A). 
The invasive capacity of H2052, H28, REN, and MM05 cells 
transfected with the ZIC1 expression constructs was impaired 
compared with control plasmid-transfected cells (Fig. 3B). To 
further test the ability of ZIC1 to act as a TSG, we assessed the 
effect of ZIC1 overexpression on the ability of H2052, H28, 
REN, and MM05 cells to form colonies. Cells transfected 
FIGURE 1. ZIC1 expression in 
mesothelioma cell lines is silenced via 
DNA methylation. A, The expression 
of ZIC1 protein was determined by 
Western blot with 40 µg total protein 
loaded in each lane, and immunob-
lotting with a ZIC1-specific anti-
body. Membrane was then stripped 
and reprobed with anti–β-actin as 
endogenous control. B, The expres-
sion of ZIC1 mRNA was determined 
by RT-qPCR in seven MPM cell lines, 
normalized to 18S and is expressed 
relative to the expression in the trans-
formed mesothelial line MeT-5A. C, 
The expression of ZIC1 mRNA after 
treatment with decitabine (5 days 
at 2 µM) was measured by RT-qPCR 
using 18S as a reference gene and 
expressed relative to untreated 
controls. D, The methylation status of 
the ZIC1 promoter was determined 
using methylation-specific PCR in the 
MPM cell lines shown in (B) and (C), 
as well as primary human mesothelial 
cells (M, methylated; U, unmethyl-
ated). E, Representative Combined 
Bisulfite Restriction Analysis of MPM 
cell lines, showing the reversal of 
ZIC1 promoter methylation in MPM 
cells after decitabine treatment. BC, 
buffy coat isolated from a healthy 
donor; IVD, universal methylated 
DNA control; MPM, malignant pleu-
ral mesothelioma.
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with the ZIC1 plasmid formed fewer colonies (Fig. 3C). The 
proliferation of all MPM lines was inhibited by overexpres-
sion of ZIC1 (Fig. 3D). Furthermore, ZIC1 overexpression 
induced apoptosis, necrosis, and death of H226, H28, and Ren 
cells (Fig. 3E).
As enforced reexpression of ZIC1 led to inhibition of 
cell proliferation, invasion, and colony formation in MPM cell 
lines with low or no detectable ZIC1 expression, we addition-
ally investigated the effects of modulating ZIC1 expression in 
MeT-5A cells. Transfecting MeT-5A cells with ZIC1-specific 
siRNA led to a decrease in ZIC1 expression (Fig. 3F) and 
resulted in an increased rate of colony formation as well as an 
enhanced ability to grow in soft agar (Fig. 3G).
ZIC1 Levels Are Associated with Changes 
in miRNA Expression in MPM Cells
Similar to others, we have shown that the expression 
of miRNAs is dysregulated in MPM cell lines and tumors, 
but the mechanism by which these changes occur remains 
unclear.23,24 As ZIC1 has been shown to have transcription 
factor activity involved in regulating mRNA expression, we 
considered whether ZIC1 could also regulate miRNA expres-
sion. Using microarray analysis we found changes in the 
expression of multiple miRNAs in MPM cells when compared 
with MeT-5A (data not shown). RT-qPCR was used to vali-
date selected microarray results, revealing that four miRNAs 
(miR-23a, miR-27a, miR-30a, and miR-30b) were higher in 
MPM cells with reduced ZIC1 expression (Fig. 4A).
Increasing ZIC1 Expression Reduces 
Expression of miR-23a/27a
The association between ZIC1 silencing and miRNA 
overexpression in MPM cell lines suggested that modulation 
of ZIC1 expression might affect expression of these miRNAs. 
To test this possibility, we overexpressed ZIC1 in H28 cells 
and tested whether the enforced expression of ZIC1 influ-
enced miRNA expression. In MPM cells transfected with the 
ZIC1 expression construct, we found that expression levels of 
miR-23a, miR-27a, miR-30a, and miR-30b were all reduced 
(Fig. 4B). As overexpression of ZIC1 led to down-regulation 
of miR-23a/27a expression and ZIC1 has DNA-binding activi-
ties,25–27 we considered whether miR-23a/27a might be a direct 
target of ZIC1. Indeed, ChIP-PCR analysis revealed direct 
binding of ZIC1 to miR-23a/27a promoter (Fig. 4C).
Suppression of miR-23a/27a Expression 
Inhibits Colony Formation in MPM Cells
As ZIC1 overexpression led to both reduced prolif-
eration and a decrease in miR-23a and miR-27a levels, we 
next tested the effect of miR-23a and miR-27a inhibition on 
MPM cell growth. Transfecting MSTO and H28 cells with an 
LNA-containing antisense oligonucleotide specific for miR-
23a or miR-27a reduced activity levels of both miRNAs and 
FIGURE 2. ZIC1 expression and 
promoter methylation in malignant 
pleural mesothelioma tumor samples. 
A, ZIC1 mRNA expression was ana-
lyzed in 24 archival tumor samples 
from patients who underwent 
extrapleural pneumonectomy (FFPE2 
to FFPE79) using RT-qPCR, with 18S 
as reference gene and with levels 
expressed relative to MeT-5A. B, 
Promoter methylation was analyzed 
by methylation-specific PCR in 24 
archival tumor samples from patients. 
DNA methylation is evident from the 
presence of the methylated (M) frag-
ment. The unmethylated fragment 
(U) was included for DNA integrity. 
ND, not detected; FFPE, formalin-
fixed paraffin-embedded.
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inhibited colony formation of MPM cells compared with cells 
treated with a negative control (Fig. 4D).
Higher Expression of miR-23a in Tumors 
Correlates with Shorter Survival
The growth inhibitory effects of decreased miR-23a 
expression in cell lines prompted us to analyze the expression 
of miR-23a in tumor samples. Expression of miR-23a was 
detected in all samples, but as histopathological subtype is a 
prognostic factor in MPM, we limited our analysis to samples 
from patients with an epithelioid subtype (Table 1). When the 
normalized levels were compared in samples from patients 
with longest survival (>30 months) versus those with shortest 
survival (<15 months), there was a significantly higher level 
FIGURE 3.  Expression of ZIC1 in 
MPM cell lines inhibits migration 
and colony formation. A, MPM cells 
were transfected with pcDNA3.1 or 
pcDNA3.1-ZIC1 and analyzed using 
immunofluorescence microscopy. 
ZIC1-specific staining is shown in 
green, with DAPI nuclear staining in 
blue. B, Invasive capacity of MPM 
cells was determined by transferring 
ZIC1- or control-transfected cells into 
24-well plates containing agarose 
spots, with invasion visualized by cells 
invading past the margin of the aga-
rose spot (dotted line). C, Clonogenic 
potential was assessed by plating 
2500 transfected cells per well of a 
six-well plate and incubating for a 
further 10 to 14 days. A representa-
tive picture from three independent 
experiments is shown, with the adja-
cent histogram showing the number 
of colonies counted. D, Cell prolifera-
tion after transfection with a ZIC1 
plasmid was measured at 48 hours 
posttransfection, and expressed as 
percentage of proliferation of control 
transfected cells (n = 3; *p < 0.05). 
E, The effect of ZIC1 transfection on 
apoptosis in MPM cells was measured 
using an Annexin-V apoptosis assay. 
A representative of two indepen-
dent experiments is shown. F, ZIC1 
expression was effectively reduced 
in MeT-5A cells with the use of a 
ZIC1-specific siRNA compared with a 
control siRNA. G, ZIC1 knock down 
increased the capacity of MeT-5A 
cells to form colonies at low density 
and increased growth in soft agar. 
The image is representative of three 
independent experiments, with the 
number of colonies counted in the 
histogram. The image in each panel 
was obtained under 10× objective 
with same magnification. MPM, 
malignant pleural mesothelioma.
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FIGURE 4.  miR-23a and miR-27a are the direct target of ZIC1. A, The expression of four miRNAs selected from miRNA profil-
ing were further analyzed by using RT-qPCR with RNU6B as a reference gene. Expression in a panel of MPM cell lines was 
normalized to MeT-5A. B, The effect of ZIC1 overexpression in H28 on levels of miR-23a, miR-27a, miR-30a, and miR-30b was 
determined by RT-qPCR. ZIC1 expression was normalized to 18S and miRNA expression was normalized to RNU6B; both are 
expressed relative to the vector control-transfected cells. Results from H28 cells are shown, with other lines showing similar 
miRNA down-regulation upon overexpression of ZIC1 (data not shown). C, ChIP-PCR using DNA from ZIC1 or control-trans-
fected cells as template. Lane 1: marker, lanes 2 and 4: ChIP-PCR from transfected cells, and lanes 3 and 5: PCR using total DNA 
as input control. D, The effect of miRNA inhibition on MPM colony formation was determined by transfecting MSTO or H28 
cells with miR-23a or miR-27a inhibitor, or control inhibitor (all 40 nM) and allowing colony formation to proceed for 14 days 
posttransfection. Images are representative of three experiments, with histograms showing the number of colonies counted in 
the presented image. E, Relative expression of miR-23a, miR-27a, miR-30a, and miR-30b in tumor samples from MPM patients 
with long or short survival (n = 8 in each group). RNU6B was used as a reference gene, and expression is normalized to the 
average of the ∆Cq of all tumors. The lines in the Tukey box plots represent the median, the boxes upper and lower limits of 
the boxes represent the 25th and 75th percentile, respectively. *p < 0.018. MPM, malignant pleural mesothelioma; ChIP-PCR, 
chromatin immunoprecipitation polymerase chain reaction.
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of miR-23a (2-fold; p = 0.018) in patients with shorter sur-
vival (Fig. 4E). A similar increase was seen for miR-27a (1.4-
fold; p = 0.114), a mature miRNA that is derived from the 
same primary transcript.
DISCUSSION
The link between asbestos exposure and MPM was 
established in the 1950s, but the carcinogenic process remains 
to be fully elucidated. In the lungs asbestos fibers are able to 
generate reactive oxygen species and free radicals causing 
DNA damage and genotoxicity.2,28–30 The high iron content of 
some asbestos fibers, as well as the propensity for asbestos 
to adsorb iron in vivo, have led to the hypothesis that iron-
induced Fenton reactions contribute to reactive oxygen spe-
cies formation, inflammation, and carcinogenesis.31 Although 
genetic deletions are relatively common in MPM, mutations 
are rare when assessed by comparative genomic hybridization 
(CGH),32 suggesting that alternative mechanisms of gene inac-
tivation may be important. The chronic inflammation elicited 
by asbestos fibers that have migrated to the mesothelium, espe-
cially the longer fibers, which can become coated with iron-
containing proteins,33 is likely to represent an important factor 
in the carcinogenesis of MPM, and this in turn may give rise to 
epigenetic changes and consequent inactivation of TSGs.
Studies of the global methylation status of MPM patients 
have shown that although there are extensive changes in the 
epigenome, distinct methylation profiles seem to exist that 
may help distinguishing MPM from non–small-cell lung can-
cer (adenocarcinoma),32,34 as well as distinguishing between 
MPM and normal pleura.35 An increased methylation status 
was found to be correlated with shorter survival, whereas a 
greater number of methylated genes was present in the sarco-
matoid subtype of MPM and in patients in whom the MPM 
diagnosis was made in a late stage.32 These studies have dem-
onstrated frequent methylation of genes controlling cell-cycle 
progression as well as other TSGs.32,34,35
The wide range of epigenetic alterations makes it difficult 
to know which genes are drivers and which are passengers,35 and 
despite extensive profiling efforts the functional consequence of 
epigenetic dysregulation in MPM has remained largely unclear. 
One exception is the contribution of hypermethylation to aber-
rant Wnt signaling in MPM. Molecular changes activating this 
pathway are well known in a variety of solid tumors, and adeno-
matous polyposis coli protein isoform expression is altered and 
β-catenin accumulates in the nucleus in MPM.36 In addition, 
members of the secreted frizzled-related protein (SFRP) fam-
ily, which act as decoy receptors antagonizing Wnt signaling, 
are epigenetically silenced in a range of tumor types.37 In MPM, 
SRFP1, 2, 4, and 5 have been shown to be down-regulated 
through promoter methylation.38,39 In the case of SFRP4, silenc-
ing was found in β-catenin–deficient MPM cells, and the resto-
ration of SFRP4 expression in these cells blocked Wnt signaling, 
suppressed growth, and induced apoptosis.39 In a subsequent 
study confirming frequent methylation-dependent silencing of 
SFRP family members, WNT inhibitory factor 1 (WIF-1) was 
also silenced by methylation in all MPM lines and the majority 
of MPM tumor specimens analyzed, in the absence of β-catenin 
mutations.38 The silencing of either WIF-1 or an SFRP gene was 
present in 95% of tumors analyzed, suggesting the involvement 
of noncanonical Wnt signaling pathways in MPM.38
In search of other genes with a potential tumor suppres-
sor roles that are silenced in MPM, we investigated ZIC1. We 
found that ZIC1 is expressed in mesothelial cells in culture 
and in normal mesothelial cells but frequently absent in MPM 
cell lines. Restoration of ZIC1 expression, either through 
decitabine treatment or with a plasmid expression construct, 
had effects similar to those observed after restoring expres-
sion of inhibitory members of the Wnt signaling pathway,38,39 
suggesting that it also functions as a TSG in MPM. The role 
of ZIC1 in MPM seems to be similar to that in gastrointestinal 
cancer, where expression is also silenced by (hyper)methyla-
tion.10,11 In colorectal10 and gastric11 cancer, ZIC1 methylation 
was observed in tumor lines and the majority of tumor sam-
ples. Similarly, ZIC1 expression was silenced in six of seven 
MPM cell lines tested and undetectable in most MPM tumor 
samples, with promoter methylation observed in the majority 
of the tumor specimens.
ZIC family members play a prominent role in neu-
ral development where they function as both transcriptional 
activators and repressors.10,11,40 Other than a small number of 
genes for which ZIC1 has been shown to directly affect expres-
sion, most changes in the expression of putative ZIC1 target 
genes have yet to be confirmed, and a consensus DNA-binding 
site is not present in directly regulated genes.12 In colorectal 
cancer cells, gene-expression profiling after overexpression 
of ZIC1 revealed an increase or decrease in the expression 
of multiple genes.10 Similarly, knockdown of ZIC1 in lipo-
sarcoma, where its overexpression seems to be oncogenic,40 
resulted in either up- or down-regulation of many genes. In the 
genes commonly affected by ZIC1 modulation in colorectal 
cancer versus liposarcoma, change in expression was in the 
opposite direction (i.e., genes up-regulated in the former were 
down-regulated in the latter and vice versa), suggesting they 
are bona fide targets of ZIC1. It is interesting to note that the 
majority of genes affected by increased expression of ZIC1 
were down-regulated, and this was also the case for the miR-
NAs we assessed, suggesting that ZIC1 has a inhibitory effect 
on both mRNA and miRNA expression.
Dysregulated miRNA expression is emerging as an 
important mechanism of gene silencing in MPM. For exam-
ple, members of the miR-200 gene family are down-regu-
lated in MPM41 and contribute to increased Wnt signaling. 
Additional studies have reported up-regulation of miRNAs of 
the miR-17–92 cluster23,42 in MPM cell lines compared with 
normal mesothelial cells, along with other miRNAs com-
monly overexpressed in solid tumors such as the miR-30 
family and miR-21.42 The effects of aberrant miRNA expres-
sion on mesothelioma cell proliferation, migration, and DNA 
methylation have been demonstrated in translational studies. 
Higher levels of miR-29c* corresponded with a favorable 
prognosis, and this seemed to be linked to posttranscriptional 
control of the expression of genes involved in DNA methyla-
tion.43 Similarly, miR-31 expression was lost in patients with 
aggressive tumors, and was found in vitro to directly repress 
expression of PPP6C, a gene with roles in cell cycle and che-
moresistance.24 In contrast, the changes in miRNA expression 
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after treatment of MPM cells with Onconase involved both 
up- and down-regulation.44 Treatment of cells with an miR-
17* mimic or a miR-30c inhibitor were able to reproduce 
the inhibitory effects of Onconase on cell proliferation and 
migration.44
Whereas miR-31 loss results from deletion of chromo-
some 9p21, a common event in MPM, the molecular basis 
underlying changes in miR-29c* and other miRNAs in MPM 
is still to be elucidated. In the present study we show that loss 
of ZIC1 leads to up-regulation of miR-23a that is convey-
ing a growth-promoting signal to MPM cells. This miRNA 
is expressed together with miR-27a and miR-24-2 in a sin-
gle transcript.45 In hepatocellular carcinoma, the expression 
of pri-23a~27a~24 was induced via transforming growth 
factor-β in a Smad-dependent manner, and this increased pro-
liferation and reduced apoptosis.46 With the molecular basis 
of altered apoptotic response that contributes to MPM drug 
resistance yet to be fully elucidated, it is tempting to speculate 
that changes in miRNAs could be involved. In this respect it 
may be important that we have observed a correlation between 
increased miR-23a and miR-27a levels and shorter survival. 
Further investigation of the relationship between ZIC1 expres-
sion, miRNA levels and apoptosis may shed more light on the 
mechanisms involved in drug resistance in MPM.
In summary, we have shown that ZIC1 acts as a TSG 
in MPM. ZIC1 is epigenetically silenced through promoter 
hypermethylation, and we provide the first evidence that ZIC1 
can control the expression of certain miRNAs. Our finding 
that ZIC1 targets apoptosis-related miRNAs, miR23a and 
miR-27a, and that these miRNAs are expressed at higher lev-
els in MPM patients with shorter survival provides a potential 
avenue for therapeutic intervention.
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